AR030492A1 - Nuevo mecanismo especifico para inhibir la adhesion de plaquetas al colageno - Google Patents

Nuevo mecanismo especifico para inhibir la adhesion de plaquetas al colageno

Info

Publication number
AR030492A1
AR030492A1 ARP010104073A ARP010104073A AR030492A1 AR 030492 A1 AR030492 A1 AR 030492A1 AR P010104073 A ARP010104073 A AR P010104073A AR P010104073 A ARP010104073 A AR P010104073A AR 030492 A1 AR030492 A1 AR 030492A1
Authority
AR
Argentina
Prior art keywords
adhesion
platquets
collagen
inhibit
specific mechanism
Prior art date
Application number
ARP010104073A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Barnes
Matthias Frech
Uwe Hofmann
Johannes Gleitz
Wolfgang Strittmatter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR030492A1 publication Critical patent/AR030492A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
ARP010104073A 2000-08-25 2001-08-27 Nuevo mecanismo especifico para inhibir la adhesion de plaquetas al colageno AR030492A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00118542 2000-08-25

Publications (1)

Publication Number Publication Date
AR030492A1 true AR030492A1 (es) 2003-08-20

Family

ID=8169664

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104073A AR030492A1 (es) 2000-08-25 2001-08-27 Nuevo mecanismo especifico para inhibir la adhesion de plaquetas al colageno

Country Status (26)

Country Link
US (2) US6881722B2 (OSRAM)
EP (1) EP1311284B1 (OSRAM)
JP (1) JP4988131B2 (OSRAM)
KR (1) KR100794277B1 (OSRAM)
CN (1) CN1224421C (OSRAM)
AR (1) AR030492A1 (OSRAM)
AT (1) ATE285246T1 (OSRAM)
AU (2) AU9550601A (OSRAM)
BR (1) BR0113478A (OSRAM)
CA (1) CA2419385C (OSRAM)
CZ (1) CZ302353B6 (OSRAM)
DE (1) DE60107962T2 (OSRAM)
DK (1) DK1311284T3 (OSRAM)
EC (1) ECSP034485A (OSRAM)
ES (1) ES2234896T3 (OSRAM)
HU (1) HU229367B1 (OSRAM)
MX (1) MXPA03001604A (OSRAM)
MY (1) MY128992A (OSRAM)
NO (1) NO331326B1 (OSRAM)
PT (1) PT1311284E (OSRAM)
RU (1) RU2302880C2 (OSRAM)
SI (1) SI1311284T1 (OSRAM)
SK (1) SK287829B6 (OSRAM)
UA (1) UA77402C2 (OSRAM)
WO (1) WO2002015919A2 (OSRAM)
ZA (1) ZA200302296B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4805461B2 (ja) * 1999-03-18 2011-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 血小板接着の阻止用タンパク質
MXPA05006043A (es) 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
US20080069774A1 (en) * 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
EP3846867B1 (en) * 2018-09-06 2025-02-19 Biomodics APS A medical tubular device
CN117229423B (zh) * 2023-11-10 2024-02-06 北京科技大学 一种用于结合胶原的多肽纳米材料及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947401A (en) * 1971-10-05 1976-03-30 Union Optics Corporation Hydrogels of unsaturated ester copolymers
US5705355A (en) 1984-03-27 1998-01-06 Transgene, S.A. Hirudin, pharmaceutical compositions comprising it and their use
US4879135A (en) * 1984-07-23 1989-11-07 University Of Medicine And Dentistry Of New Jersey Drug bonded prosthesis and process for producing same
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
IL86857A (en) * 1988-06-24 1994-04-12 Yissum Res Dev Co Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
CA2052486A1 (en) * 1990-10-09 1992-04-10 Thomas M. Connolly Protein for inhibiting collagen-stimulated platelet aggregation
GB9022040D0 (en) 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
US5179082A (en) * 1990-11-13 1993-01-12 Merck & Co., Inc. Method for blocking platelet adhesion to collagen
ATE169674T1 (de) * 1991-09-05 1998-08-15 Schering Ag Hemmstoff der kollagen-induzierten plättchenaggregation
DE4136513A1 (de) 1991-11-06 1993-05-13 Basf Ag Neues thrombininhibitorisches protein aus raubwanzen
JP3742429B2 (ja) 1993-07-01 2006-02-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング コラーゲン刺激血小板凝集の阻害剤
ES2255477T5 (es) * 1993-07-29 2010-04-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Uso de paclitaxel y sus derivados en la fabricacion de un medicamento para el tratamiento de reestenosis.
US5532287A (en) * 1994-05-04 1996-07-02 Ciba-Geigy Corporation Radiation cured drug release controlling membrane
US5767108A (en) * 1995-08-22 1998-06-16 Medtronic, Inc. Method for making improved heparinized biomaterials
US6246715B1 (en) * 1998-06-26 2001-06-12 Samsung Electronics Co., Ltd. Data transmitter and receiver of a DS-CDMA communication system
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
WO2000023094A2 (en) * 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment
IT1304135B1 (it) * 1998-11-26 2001-03-07 Magneti Marelli Spa Metodo di controllo dell' iniezione e dell' accensione in un motoreendotermico ad iniezione diretta per accelerare il riscaldamento del
JP2002537270A (ja) * 1999-02-19 2002-11-05 ザイモジェネティクス，インコーポレイティド 止血及び免疫機能における使用のためのインヒビター
JP4805461B2 (ja) 1999-03-18 2011-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 血小板接着の阻止用タンパク質

Also Published As

Publication number Publication date
NO20030841L (no) 2003-02-24
HUP0303747A3 (en) 2006-01-30
HU229367B1 (en) 2013-11-28
UA77402C2 (en) 2006-12-15
CZ302353B6 (cs) 2011-03-30
ES2234896T3 (es) 2005-07-01
US20030190342A1 (en) 2003-10-09
CN1224421C (zh) 2005-10-26
CA2419385A1 (en) 2002-02-28
ATE285246T1 (de) 2005-01-15
WO2002015919A3 (en) 2002-05-30
US6881722B2 (en) 2005-04-19
HK1059736A1 (en) 2004-07-16
ZA200302296B (en) 2004-06-30
KR20030034141A (ko) 2003-05-01
ECSP034485A (es) 2003-03-31
AU9550601A (en) 2002-03-04
AU2001295506B2 (en) 2007-02-15
CN1449291A (zh) 2003-10-15
JP4988131B2 (ja) 2012-08-01
RU2302880C2 (ru) 2007-07-20
DE60107962T2 (de) 2005-12-15
MY128992A (en) 2007-03-30
MXPA03001604A (es) 2003-06-04
KR100794277B1 (ko) 2008-01-11
NO331326B1 (no) 2011-11-28
NO20030841D0 (no) 2003-02-24
HUP0303747A2 (hu) 2004-03-01
EP1311284A2 (en) 2003-05-21
EP1311284B1 (en) 2004-12-22
CA2419385C (en) 2011-05-10
PT1311284E (pt) 2005-05-31
BR0113478A (pt) 2003-07-15
DK1311284T3 (da) 2005-04-18
US20050143305A1 (en) 2005-06-30
WO2002015919A2 (en) 2002-02-28
CZ2003720A3 (cs) 2003-06-18
SK3132003A3 (en) 2003-08-05
SI1311284T1 (OSRAM) 2005-08-31
SK287829B6 (sk) 2011-11-04
PL359246A1 (en) 2004-08-23
US7459438B2 (en) 2008-12-02
DE60107962D1 (de) 2005-01-27
JP2004506690A (ja) 2004-03-04

Similar Documents

Publication Publication Date Title
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
PA8759601A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
ES2191480T3 (es) Protesis endovasculares con revestimientos bioactivos.
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
AR040305A1 (es) Vendaje hemostatico para heridas que contiene un polisacarido modificado con aldehido y agentes hemostaticos
PT2336184E (pt) Administração de agentes para o tratamento da inflamação
BR0109729A (pt) Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese
DE60237302D1 (de) Stent zur abgabe einer therapeutischen substanz oder anderer mittel
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
AR021535A1 (es) Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo
CY1105941T1 (el) ΡΕΤΙΝΟΕΙΔΙΚΟΙ ΑΓΩΝΙΣΤΕΣ ΕΚΛΕΚΤΙΚΟΙ ΩΣ ΠΡΟΣ RARγ ΓΙΑ ΤΗ ΘEPΑΠΕΙΑ ΤΟΥ ΕΜΦΥΣΗΜΑΤΟΣ
BR0008254A (pt) Combinações para o tratamento de doenças que envolvam angiogênese
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
AR030492A1 (es) Nuevo mecanismo especifico para inhibir la adhesion de plaquetas al colageno
BR9807523A (pt) Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids.
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
ES2421407T3 (es) Agente y composición para la curación de heridas
CL2004001186A1 (es) Uso de una combinacion farmaceutica de un ligando selectivo erb y un agente anti-artritis para preparar un medicamento util en el tratamiento o la inhibicion de la artritis en un mamifero.
SV2002000639A (es) Alcanosulfonatos de fenoxifenilo ref. lea 34813-sv
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
ES2067221T3 (es) Activador de plasminogeno del tejido que tiene propiedades especificas para la fibrina.

Legal Events

Date Code Title Description
FC Refusal